|
KMID : 1039420170510030242
|
|
Journal of Pathology and Translational Medicine
2017 Volume.51 No. 3 p.242 ~ p.254
|
|
|
Molecular Testing of Lung Cancers
|
|
Shim Hyo-Sup
Choi Yoon-La
Kim Lucia
Chang Sun-Hee
Kim Wan-Seop
Roh Mee-Sook
Kim Tae-Jung
Ha Seung-Yeon
Chung Haeng
Jang Se-Jin
Lee Geon-Kook
|
|
|
Abstract
|
|
|
|
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories?mutations, gene rearrangements, and amplifications?and propose expanded guidelines on molecular testing of lung cancers.
|
|
|
KEYWORD
|
|
|
Lung neoplasms, Molecular testing, Guideline, Precision medicine
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|